Compare Stocks → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATXNYSE:FTTCVE:RVV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXCosta$2,934.88$0.00▼$0.00N/AN/AN/AN/AFTTFederated Enhanced Treasury Income Fund$0.00$12.81▼$13.82N/AN/A24,050 shsN/ARVVRevive TherapeuticsC$0.08+14.3%C$0.08C$0.07▼C$0.25C$5.79MN/A93,085 shs212,852 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXCosta0.00%0.00%0.00%0.00%0.00%RVVRevive Therapeutics0.00%0.00%0.00%0.00%0.00%Altcoin FRENZY Alert… (Ad)Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!)MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXCostaN/AN/AN/AN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AN/AN/AN/ARVVRevive TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXCostaN/AN/AN/AN/AFTTFederated Enhanced Treasury Income Fund3.00Buy$50.00∞ UpsideRVVRevive TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXCostaN/AN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AN/ARVVRevive TherapeuticsN/AN/AC$0.03 per share3.18C$0.02 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXCostaN/AN/A0.00N/AN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/A0.00N/AN/AN/AN/AN/AN/ARVVRevive TherapeuticsN/A-C$0.02N/A∞N/AN/AN/AN/A6/4/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXCostaN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/ARVVRevive TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXCostaN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/ARVVRevive TherapeuticsN/A6.146.03OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXCostaN/AFTTFederated Enhanced Treasury Income FundN/ARVVRevive TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipATXCostaN/AFTTFederated Enhanced Treasury Income FundN/ARVVRevive TherapeuticsN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATXCostaN/AN/AN/ANot OptionableFTTFederated Enhanced Treasury Income FundN/AN/AN/ANot OptionableRVVRevive TherapeuticsN/A72.41 millionN/ANot OptionableFTT, ATX, PYC, RVV, and FIJ HeadlinesSourceHeadlineRevive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDfinanznachrichten.de - March 27 at 4:23 PMRevive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDfinance.yahoo.com - March 27 at 10:10 AMRevive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDfinanznachrichten.de - March 19 at 11:42 AMRevive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDmarkets.businessinsider.com - March 19 at 11:42 AMRevive Therapeutics Ltd.: Revive Therapeutics Provides Corporate Updatefinanznachrichten.de - March 12 at 8:23 AMRevive Therapeutics Provides Corporate Updatefinancialpost.com - March 12 at 7:08 AMRevive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110markets.businessinsider.com - February 26 at 8:53 PMRevive Therapeutics Explores the Use of Bucillamine for Long COVIDmarkets.businessinsider.com - February 1 at 9:20 AMRevive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500markets.businessinsider.com - January 31 at 7:29 PMRevive Therapeutics Ltd. Announces Offering of Up to $3 Millionfinancialpost.com - January 24 at 7:03 PMRevive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canadatmcnet.com - January 16 at 8:29 AMRevive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillaminefinanznachrichten.de - January 10 at 2:05 PMRevive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillaminemarkets.businessinsider.com - January 10 at 9:05 AMTravere Therapeutics expects Q4 net product sales from continuing operations to be about $40Mmsn.com - January 8 at 4:03 PMRevive Therapeutics Announces Results of Annual General and Special Meeting of Shareholdersmarkets.businessinsider.com - December 20 at 5:50 PMRevive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of Bucillaminemarkets.businessinsider.com - December 18 at 8:03 AMRevive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillaminefinancialpost.com - December 18 at 7:07 AMRevive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposuremarkets.businessinsider.com - October 17 at 4:48 PMRevive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent Exposuremarkets.businessinsider.com - October 17 at 11:47 AMRevive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation Developmentfinanznachrichten.de - October 11 at 2:48 PMRevive Therapeutics Provides Update of Novel Bucillamine Formulation Developmenttmcnet.com - October 11 at 9:47 AMRevive I-5 project continues with driving surface improvement work starting Mondaykomonews.com - October 11 at 12:00 AMItaly turns to Kyrgyz shepherds to revive Sardinian farmingft.com - September 28 at 9:58 AMMississippi should revive process to put issues on ballot, Secretary of State Watson saysclarionledger.com - September 23 at 8:18 AMMedia Sentiment Over TimeCompany DescriptionsCostaNASDAQ:ATXCosta Inc, formerly A. T. Cross Company is a designer and marketer of branded personal accessories, including writing instruments, reading glasses, personal and business accessories and sunglasses. The Company's Cross Optical Group (COG) consists of its wholly owned subsidiary, Cross Optical Group, Inc. and is the legal entity of the Company's two sunglass brands: Costa and Native. The Company's COG designs, manufactures and markets polarized sunglasses under the brand names Costa and Native. The Company's brands offer sunglasses in more than 75 styles and 25 lens options. In September 2013, the Company sold its Cross Accessory Division and the rights to the A.T. Cross name, which was associated with the writing instrument business. Effective February 3, 2014, Essilor International SA acquired Costa Inc.Federated Enhanced Treasury Income FundNYSE:FTTFederated Premier Intermediate Municipal Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is to provide current income exempt from federal income tax, including the federal alternative minimum tax (AMT). The Fund's portfolio of investments include various sectors namely transportation, special tax, hospital, education, public power, senior care, water and sewer, general obligation-local, industrial development bond/pollution control revenue and general obligation-state. The Fund invests in intermediate-term, tax-exempt municipal bonds diversified among states, sectors and issuers. Federated Investment Management Company is the advisor of the Fund.Revive TherapeuticsCVE:RVVRevive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.